Anticancer Effect of Medicinal Mushroom with Prooxidant Activity on Human Bladder Cancer Cells

Cristina Fox¹, Roger Yau¹, Muhammad Choudhury¹, John Phillips¹ and Sensuke Konno^1,

¹Department of Urology, New York Medical College, Valhalla, New York, USA

Cite this paper:
Cristina Fox, Roger Yau, Muhammad Choudhury, John Phillips and Sensuke Konno. Anticancer Effect of Medicinal Mushroom with Prooxidant Activity on Human Bladder Cancer Cells. Journal of Cancer Research and Treatment. 2018; 6(2):54-59. doi: 10.12691/jcrt-6-2-5

Abstract

Oxidative stress (OXS) has been recently considered as one of anticancer strategies by taking advantage of higher vulnerability of cancer cells (than normal cells) to OXS. In fact, the successful outcomes using OXS have been reported in several cancer cases. A medicinal mushroom extract, PE isolated from Poria mushroom, has been shown to have anticancer/antitumor activity, although its anticancer mechanism has not been fully understood but may involve OXS. We investigated if PE might have anticancer effect on human bladder cancer cells through OXS in vitro. A dose-dependent (0-200 μg/ml of PE) study was first performed to assess cell viability using MTT assay. PE led to a significant reduction in cell viability with the IC₅₀ (50% inhibitory concentration) of 100 μg/ml. A possible anticancer role of OXS was then assessed by lipid peroxidation (LPO) assay. The results indicated that PE indeed exerted ~2.1-fold greater OXS (than controls) on the cells. The anticancer mechanism of PE was further explored, focusing on glycolysis, metabolic signaling pathways, and apoptosis. Two glycolytic parameters, hexokinase (HK) activity and cellular ATP level, have significantly declined, suggesting the inhibition of glycolysis. Coupled with the reduced ATP level, AMP-activated protein kinase (AMPK) was activated, while protein kinase B (Akt) was inactivated and concomitantly mammalian target of rapamycin (mTOR) was inhibited. These results imply the growth cessation, followed by cell death. Western blot analysis also revealed that such cell death was more likely linked to apoptosis, indicated by the bcl-2 down-regulation and the Bax up-regulation. Therefore, PE is a natural anticancer agent with prooxidant activity exerting OXS, which leads to inhibition of glycolysis, modulations of metabolic signaling pathways, and ultimately apoptosis. It may have clinical implications in oral and/or intravesical administration for a safer and better therapeutic option for bladder cancer.

Keywords:
anticancer oxidative stress mushroom prooxidant bladder cancer

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics 2017. CA Cancer J Clin. 2017; 67(1): 7-30.
[2]	Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control. 2000; 7(4): 335-339.
[3]	Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374(9685): 239-249.
[4]	Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9): 859-866.
[5]	Rios JL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 2011; 77(7): 681-691.
[6]	Zhou L, Zhang Y, Gapter LA, Ling H, Agarwal R, Ng KY. Cytotoxic and antioxidant activities of lanostane-type triterpenes isolated from Poria cocos. Chem Pharm Bull (Tokyo). 2008; 56(10): 1459-1462.
[7]	Chen X, Zhang L, Cheung PC. Immunopotentiation and anti-tumor activity of carboxymethylated-sulfated β-(1→3)-D-glucan from Poria cocos. Int Immunopharmacol. 2010; 10(4): 398-405.
[8]	Zhao YY, Lei P, Chen DQ, Feng YL, Bai X. Renal metabolic profiling of early renal injury and renoprotective effects of Poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. J Pharm Biomed Anal. 2013; 81-82: 202-209.
[9]	Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis. 1997; 29(3): 465-477.
[10]	Han MH, Park C, Jin CY, et al. Apoptosis induction of human bladder cancer cells by sanguinarine through reactive oxygen species-mediated up-regulation of early growth response gene-1. PLoS One. 2013; 8(5): e63425.
[11]	Leung PY, Miyashita K, Young M, Tsao CS. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res. 1993; 13(2): 475-480.
[12]	Prosperini A, Juan-Garcia A, Font G, Ruiz MJ. Reactive oxygen species involvement in apoptosis and mitochondrial damage in Caco-2 cells induced by enniatins A, A1, B and B1. Toxicol Lett. 2013; 222(1): 36-44.
[13]	Shin HR, You BR, Park WH. PX-12-induced HeLa cell death is associated with oxidative stress and GSH depletion. Oncol Lett. 2013; 6(6): 1804-1810.
[14]	Uetaki M, Tabata S, Nakasuka F, Soga T, Tomita M. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci Rep. 2015; 5: 13896.
[15]	Dargel R. Lipid peroxidation: a common pathogenetic mechanism? Exp Toxic Pathol. 1992; 44(4): 169-181.
[16]	Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25(34): 4633-4646.
[17]	Simons AL, Mattson DM, Dornfeld K, Spitz DR. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther. 2009; 5(Suppl 1): S2-6.
[18]	Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J. 1996; 313(Pt 3): 957-962.
[19]	Cheong JH, Park ES, Liang J, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011; 10(12): 2350-2362.
[20]	Priebe A, Tan L, Wahl H, et al. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol. 2011; 122(2): 389-395.
[21]	Lee YK, Park OJ. Regulation of mutual inhibitory activities between AMPK and Akt with quercetin in MCF-7 breast cancer cells. Oncol Rep. 2010; 24(6): 1493-1497.
[22]	Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002; 277(27): 23977-23980.
[23]	Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50): 6398-6406.
[24]	Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond). 2008; 32(Suppl 4): S36-41.
[25]	MacFarlane M, Robinson GL, Cain K. Glucose – a sweet way to die: metabolic switching modulates tumor cell death. Cell Cycle. 2012; 11(21): 3919-3925.